- Bupa Platinum consultant
- Fee assured
- Awaiting verification
- Open Referral network
Specialises in
- Breast
Offers
- Face-to-face consultations
- Video and telephone consultations
About me
Dr Sophie McGrath is a Consultant Medical Oncologist at The Royal Marsden Hospital, specialising in Breast Cancer and Acute Oncology. She studied medicine and undertook her Oncology training in London. She was awarded a PhD from the University of Surrey in 2015, researching biomarkers for early diagnosis, prognosis and treatment response in ovarian cancer.
Dr McGrath has worked as a Consultant at The Royal Marsden and Kingston Hospitals since February 2017, providing compassionate, patient-centred clinical care, to complement her broad experience of chemotherapy, hormonal and targeted therapy, as well as immunotherapy prescribing.
Her additional experience as an Acute Oncologist provides a wealth of knowledge around the management of side-effects due to treatment. She has played a pivotal role in the development of the Acute Oncology Service at the Sutton site since 2017.
Dr McGrath is Principle and Sub-Investigator for numerous breast cancer clinical trials, and has particular research interests in digital technology to promote patient activation and engagement in early breast cancer, as well as acute symptom monitoring and management.
She is a member of The Royal Marsden’s Drugs and Therapeutics Committee, Acute Oncology Group, and Sepsis Steering Committee.
Medical secretaries
- Ms Yvonne Slater
- Royal Marsden Hospital Department of Medicine, Breast Unit Downs Road Sutton SM2 5PT
- 020 8661 3276
- yvonne.slater2@rmh.nhs.uk
Information for healthcare professionals (Bupa patients only, last 12 months)
-
X0004
Clinical supervision and planning for the delivery of chemotherapy and/or systemic anti-cancer therapy for 1-28 days - (5-50)
The Royal Marsden Hospital (5-50)
-
X0003
Clinical supervision and planning for the delivery of chemotherapy and/or systemic anti-cancer therapy for 1-21 days - (5-50)
-
X0002
Clinical supervision and planning for the delivery of chemotherapy and/or systemic anti-cancer therapy for 1-14 days - (5-50)